Tislelizumab

Generic Name: Tislelizumab

Brand Names: Tevimbra, Tizveni

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1858168-59-8

Unique Ingredient Identifier: 0KVO411B3N

Background: Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).

Indication: ⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。

⑵用于治疗局部晚期或转移性尿路上皮癌。

⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。

⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。

⑸用于治疗晚期恶性实体瘤

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)

Phase 2

Recruiting

Conditions: DLBCL

Interventions: Drug: Tislelizumab
Drug: Pemetrexed

First Posted Date: 2022-02-23

Last Posted Date: 2024-04-17

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 28

Registration Number: NCT05253118

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Renal Cell Carcinoma
Sarcoma
Mesothelioma
Gastric Cancer
Melanoma
Non Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Testicular Germ Cell Tumor
Cervical Cancer

Interventions: Drug: HFB200301
Drug: Tislelizumab

First Posted Date: 2022-02-14

Last Posted Date: 2024-05-01

Lead Sponsor: HiFiBiO Therapeutics

Target Recruit Count: 170

Registration Number: NCT05238883

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
NEXT Virginia Cancer Specialists, Fairfax, Virginia, United States

and more 5 locations

A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.

Phase 2

Not yet recruiting

Conditions: Colon Cancer

Interventions: Drug: Tislelizumab

First Posted Date: 2022-02-09

Last Posted Date: 2022-02-09

Lead Sponsor: The First Affiliated Hospital of Zhengzhou University

Target Recruit Count: 70

Registration Number: NCT05231850

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

Phase 2

Active, not recruiting

Conditions: Lung Cancer, Small Cell

Interventions: Drug: Tislelizumab
Drug: Sitravatinib

First Posted Date: 2022-02-08

Last Posted Date: 2023-09-26

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 21

Registration Number: NCT05228496

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Phase 2

Recruiting

Conditions: Immunotherapy
Gastrict Cancer

Interventions: Drug: Tislelizumab
Drug: Apatinib Mesylate
Drug: oxaliplatin
Drug: Tegafur

First Posted Date: 2022-02-03

Last Posted Date: 2023-01-18

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT05223088

Locations: 🇨🇳
Fujian cancer hospital, Fuzhou, China

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Phase 3

Active, not recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Placebo
Drug: Tislelizumab

First Posted Date: 2022-01-27

Last Posted Date: 2024-04-18

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 450

Registration Number: NCT05211232

Locations: 🇨🇳
The Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong, China
🇨🇳
Wuzhou Red Cross Hospital, Wuzhou, Guangxi, China
🇨🇳
Guizhou Cancer Hospital, Guiyang, Guizhou, China

and more 1 locations

Tislelizumab as Cross-line Treatment for Advanced NSCLC

Phase 2

Conditions: Advanced Non-small-cell Lung Cancer

Interventions: Drug: Tislelizumab

First Posted Date: 2022-01-14

Last Posted Date: 2022-01-14

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 35

Registration Number: NCT05192681

Locations: 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Stage IV Prostate Cancer
Prostate Cancer

Interventions: Drug: Luteinizing Hormone Releasing Hormone
Drug: New Hormonal Agent
Drug: Docetaxel
Drug: Tislelizumab

First Posted Date: 2022-01-12

Last Posted Date: 2024-11-29

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 32

Registration Number: NCT05189457

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Tislelizumab
Drug: Sitravatinib

First Posted Date: 2022-01-04

Last Posted Date: 2024-01-29

Lead Sponsor: Fudan University

Target Recruit Count: 5

Registration Number: NCT05176925

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer

Recruiting

Conditions: Radiation Oncology
Rectal Cancer

Interventions: Radiation: split-course HFRT
Drug: CAPOX chemotherapy
Drug: Tislelizumab

First Posted Date: 2022-01-04

Last Posted Date: 2023-09-25

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 50

Registration Number: NCT05176964

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy